Shares of ZimVie Inc. (NASDAQ:ZIMV – Get Free Report) have been given a consensus recommendation of “Reduce” by the five research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $17.75.
A number of brokerages recently weighed in on ZIMV. Weiss Ratings restated a “sell (d-)” rating on shares of ZimVie in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of ZimVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 18th. B. Riley downgraded shares of ZimVie from a “buy” rating to a “neutral” rating and set a $19.00 price objective on the stock. in a research report on Thursday, July 31st. Finally, Barclays upgraded shares of ZimVie from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $9.00 to $19.00 in a research report on Tuesday, July 22nd.
Get Our Latest Stock Report on ZimVie
Institutional Inflows and Outflows
ZimVie Stock Performance
Shares of NASDAQ ZIMV opened at $18.99 on Tuesday. The firm’s 50 day moving average price is $18.93 and its 200-day moving average price is $14.23. The company has a market cap of $535.71 million, a PE ratio of -27.13 and a beta of 2.17. ZimVie has a 52-week low of $8.15 and a 52-week high of $19.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.60 and a current ratio of 2.37.
ZimVie (NASDAQ:ZIMV – Get Free Report) last issued its earnings results on Monday, April 1st. The company reported $0.07 earnings per share (EPS) for the quarter. The firm had revenue of ($221.45) million for the quarter. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. On average, equities research analysts expect that ZimVie will post 0.6 EPS for the current fiscal year.
ZimVie Company Profile
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Featured Stories
- Five stocks we like better than ZimVie
- What Are Trending Stocks? Trending Stocks Explained
- Is Beyond Meat a Buy After Meme Stock Surge? Analysts Say No
- 3 Ways To Invest In Coffee, Other Than Drinking It
- ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Super Micro’s Moment of Truth: A Growth Story Under Pressure
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.
